textabstractIntroduction: Introducing biosimilar infliximab for the treatment in rheumatology (rheumatoid arthritis and ankylosing spondylitis) and inflammatory bowel disease (Crohn's disease and ulcerative colitis) may reduce treatment costs associated with biologics. This study aimed to investigate the budget impact of adopting biosimilar infliximab in five European countries, considering that the budget impact includes the adoption of biosimilar infliximab and the availability of biologic alternatives such as vedolizumab, biosimilar etanercept, biosimilar rituximab, and other relevant factors. Methods: An existing budget impact model was adapted to forecast the budget impact in the UK, Germany, France, Spain, and Italy. Epidemiological p...
International audienceAbstract TNF-alpha inhibitors have revolutionized the therapeutic care in chro...
As patents for first-to-market biologics expire, subsequent-entry products – biosimilars – can becom...
Objective: To compare the market dynamics of biosimilar infliximab among four Organization for Econo...
Introduction: Introducing biosimilar infliximab for the treatment in rheumatology (rheumatoid arthri...
Introduction: Introducing biosimilar infliximab for the treatment in rheumatology (rheumatoid arthri...
International audienceAbstract Background In 2020, the European Medicines Agency approved infliximab...
Item does not contain fulltextObjective: Inflammatory bowel disease [IBD] entails a high economic bu...
Abstract The first biosimilar monoclonal antibody (inf-liximab, CT-P13) was registered by the Europe...
Background: The introduction of biosimilars can be a chance to significantly impact on the sustainab...
OBJECTIVE: Biological disease-modifying antirheumatic drugs (bDMARDs) are effective but expensive op...
Objectives: To understand economic implications following the recommendation set in 2015 by Tuscan H...
Biological therapies are an effective treatment for a range of immune-mediated inflammatory diseases...
Background: The approval of new biosimilars of infliximab, etanercept and adalimumab by the Europea...
Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis determine a high cos...
International audienceAbstract TNF-alpha inhibitors have revolutionized the therapeutic care in chro...
As patents for first-to-market biologics expire, subsequent-entry products – biosimilars – can becom...
Objective: To compare the market dynamics of biosimilar infliximab among four Organization for Econo...
Introduction: Introducing biosimilar infliximab for the treatment in rheumatology (rheumatoid arthri...
Introduction: Introducing biosimilar infliximab for the treatment in rheumatology (rheumatoid arthri...
International audienceAbstract Background In 2020, the European Medicines Agency approved infliximab...
Item does not contain fulltextObjective: Inflammatory bowel disease [IBD] entails a high economic bu...
Abstract The first biosimilar monoclonal antibody (inf-liximab, CT-P13) was registered by the Europe...
Background: The introduction of biosimilars can be a chance to significantly impact on the sustainab...
OBJECTIVE: Biological disease-modifying antirheumatic drugs (bDMARDs) are effective but expensive op...
Objectives: To understand economic implications following the recommendation set in 2015 by Tuscan H...
Biological therapies are an effective treatment for a range of immune-mediated inflammatory diseases...
Background: The approval of new biosimilars of infliximab, etanercept and adalimumab by the Europea...
Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis determine a high cos...
International audienceAbstract TNF-alpha inhibitors have revolutionized the therapeutic care in chro...
As patents for first-to-market biologics expire, subsequent-entry products – biosimilars – can becom...
Objective: To compare the market dynamics of biosimilar infliximab among four Organization for Econo...